The Phe-124-Cys and A-161T variants of the human 5-HT1B receptor gene are not major determinants of the clinical response to sumatriptan

Headache

Volumn 47, Issue 5, 2007, Pages 711-716

  Mehrotra, Suneet ^a   Vanmolkot, Kaate R J ^b   Frants, Rune R ^b   Van Den Maagdenberg, Arn M J M ^b   Ferrari, Michel D ^b   MaassenVanDenBrink, Antoinette ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5 HT1B receptor; Migraine; Polymorphism; Sumatriptan

Indexed keywords

CYSTEINE; GENOMIC DNA; PHENYLALANINE; SEROTONIN 1B RECEPTOR; SUMATRIPTAN;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG RESPONSE; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC SCREENING; HUMAN; MALE; MIGRAINE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE; RECURRENT DISEASE; THORAX PAIN; TREATMENT OUTCOME;

ADULT; AGED; CYSTEINE; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PHARMACOGENETICS; PHENYLALANINE; RECEPTOR, SEROTONIN, 5-HT1B; SEROTONIN AGONISTS; SUMATRIPTAN; TREATMENT OUTCOME; VARIATION (GENETICS);

EID: 34248330860     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2007.00792.x     Document Type: Article

References (30)

1. Goadsby PJ. Advances in the pharmacotherapy of migraine. How knowledge of pathophysiology is guiding drug development. Drugs R D. 1999 2 : 361 374.
2. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002 22 : 633 658.
3. Ferrari MD, Saxena PR. 5-HT1 receptors in migraine pathophysiology and treatment. Eur J Neurol. 1995 2 : 5 21.
4. Ferrari MD, Saxena PR. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol Sci. 1993 14 : 129 133.
5. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1994 47 : 622 651.
6. Visser WH, de Vriend RHM, Jaspers NMWH, Ferrari MD. Sumatriptan in clinical practice: A 2-year review of 453 migraine patients. Neurology. 1996 47 : 46 51.
7. Visser WH, Jaspers NMWH, de Vriend RHM, Ferrari MD. Chest symptoms after sumatriptan: A two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia. 1996 16 : 554 559.
8. Visser WH, Burggraaf J, Muller LM, et al Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin Pharm Ther. 1996 60 : 452 460.
9. Gupta S, Jain S, Brahmachari SK, Kukreti R. Pharmacogenomics: A path to predictive medicine for schizophrenia. Pharmacogenomics. 2006 7 : 31 47.
10. Sakurai A, Tamura A, Onishi Y, Ishikawa T. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: Therapeutic implications. Expert Opin Pharmacother. 2005 6 : 2455 2473.
11. De Vries B, Haan J, Frants RR, Van den Maagdenberg AMJM, Ferrari MD. Genetic biomarkers for migraine. Headache. 2006 46 : 1059 1068.
12. Koo SH, Lee EJ. Pharmacogenetics approach to therapeutics. Clin Exp Pharmacol Physiol. 2006 33 : 525 532.
13. van den Broek RWM, Bhalla P, MaassenVanDenBrink A, de Vries R, Sharma HS, Saxena PR. Characterization of sumatriptan-induced contractions in human isolated blood vessels using selective 5-HT1B and 5-HT1D receptor antagonists and in situ hybridization. Cephalalgia. 2002 22 : 83 93.
14. Wackenfors A, Jarvius M, Ingemansson R, Edvinsson L, Malmsjo M. Triptans induce vasoconstriction of human arteries and veins from the thoracic wall. J Cardiovasc Pharmacol. 2005 45 : 476 484.
15. MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 1998 98 : 25 30.
16. MaassenVanDenBrink A, Vergouwe MN, Ophoff RA, Saxena PR, Ferrari MD, Frants RR. 5-HT1B receptor polymorphism and clinical response to sumatriptan. Headache. 1998 38 : 288 291.
17. Nöthen MM, Erdmann J, Shimron-Abarbanell D, Propping P. Identification of genetic variation in the human serotonin1Dß receptor gene. Biochem Biophys Res Communications. 1994 205 : 1194 1200.
18. Brüss M, Bonisch H, Bühlen M, Nöthen MM, Propping P, Göthert M. Modified ligand binding to the naturally occurring Cys-124 variant of the human serotonin 5-HT1B receptor. Pharmacogenetics. 1999 9 : 95 102.
19. Kiel S, Brüss M, Bonisch H, Göthert M. Pharmacological properties of the naturally occurring Phe-124-Cys variant of the human 5-HT1B receptor: Changes in ligand binding, G-protein coupling and second messenger formation. Pharmacogenetics. 2000 10 : 655 666.
20. Verheggen R, Werner I, Lucker A, Brüss M, Göthert M, Kaumann AJ. 5-Hydroxytryptamine-induced contraction of human temporal arteries coexpressing 5-HT2A receptors and wild-type or variant (Phe124Cys) 5-HT1B receptors: Increased contribution of 5-HT1B receptors to the total contractile amplitude in arteries from Phe124Cys heterozygous individuals. Pharmacogenet Genomics. 2006 16 : 601 607.
21. Sun HF, Chang YT, Fann CS, et al Association study of novel human serotonin 5-HT1B polymorphisms with alcohol dependence in Taiwanese Han. Biol Psychiatry. 2002 51 : 896 901.
22. Olesen J, Goadsby PJ, Steiner T. The International Classification of Headache Disorders. Lancet Neurol. 2003 2.
23. Ott J. Analysis of Human Genetic Linkage. Baltimore : Johns Hopkins University Press 1999.
24. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res. 1988 16 : 1215.
25. Nöthen MM, Erdmann J, Shimron-Abarbanell D, Propping P. Identification of genetic variation in the human serotonin 1D beta receptor gene. Biochem Biophys Res Commun. 1994 205 : 1194 1200.
26. Villalón CM, Centurión D, Valdivia LF, de Vries P, Saxena PR. Migraine: Pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol. 2003 1 : 71 84.
27. Gómez-Mancilla B, Cutler NR, Leibowitz MT, et al Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia. 2001 21 : 727 732.
28. Villalón CM, Centurión D, Valdivia LF, De Vries P, Saxena PR. An introduction to migraine: From ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002 45 : 199 210.
29. MaassenVanDenBrink A, Vergouwe MN, Ophoff RA, et al Chromosomal localization of the 5-HT1F receptor gene: No evidence for involvement in response to sumatriptan in migraine patients. Am J Med Genet. 1998 77 : 415 420.
30. Dahlöf CG. Infrequent or non-response to oral sumatriptan does not predict response to other triptans-review of four trials. Cephalalgia. 2006 26 : 98 106.